Clinical Trial Update: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating trastuzumab deruxtecan in hormone receptor-negative and hormone receptor-positive HER2-low or HER2 IHC 0 metastatic breast cancer is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)
• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Breast Cancer | Phase 3 | Status: RECRUITING